NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $2.34 +0.05 (+2.18%) Closing price 04:00 PM EasternExtended Trading$2.37 +0.03 (+1.07%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CytomX Therapeutics Stock (NASDAQ:CTMX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytomX Therapeutics alerts:Sign Up Key Stats Today's Range$2.21▼$2.3650-Day Range$2.22▼$3.7252-Week Range$2.16▼$8.21Volume4.94 million shsAverage Volume3.44 million shsMarket Capitalization$509.89 millionP/E RatioN/ADividend YieldN/APrice Target$11.90Consensus RatingModerate Buy Company Overview CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites. CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines. Its pipeline has included oncology candidates directed at targets such as EGFR, CD3, and CEACAM5, with programs being evaluated in areas including solid tumors and hematologic malignancies. These medicines remain investigational and have not been established as approved commercial products. Founded in 2008 and headquartered in South San Francisco, California, CytomX has conducted research and clinical development activities for patients in the United States and other international markets. The company has also pursued collaborations with larger pharmaceutical companies, including agreements involving the development of Probody-based therapeutics. CytomX’s shares trade on the Nasdaq under the symbol CTMX.AI Generated. May Contain Errors. Read More CytomX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCTMX MarketRank™: 2.18439716312 of 5 starsCytomX Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 647th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCytomX Therapeutics has a consensus price target of $11.90, representing about 408.5% upside from its current price of $2.34.Amount of Analyst CoverageCytomX Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CytomX Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CytomX Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.41% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 13.78, which indicates bearish sentiment.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 4.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.14 News SentimentCytomX Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for CytomX Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows3 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTMX Stock News HeadlinesCytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026October 29 at 8:00 AM | globenewswire.comJanux Therapeutics (NASDAQ:JANX) vs. CytomX Therapeutics (NASDAQ:CTMX) Head to Head SurveyOctober 26, 2026 | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 30 at 1:00 AM | Weiss Ratings (Ad)CytomX Therapeutics Sees Unusually Large Options Volume (NASDAQ:CTMX)October 23, 2026 | americanbankingnews.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Has Consensus Target Price of $11.90 According to AnalystsOctober 22, 2026 | americanbankingnews.comCytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comCytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - SlideshowSeptember 10, 2026 | seekingalpha.comCytomX Therapeutics to Present at Upcoming September Investor ConferencesSeptember 1, 2026 | globenewswire.comSee More Headlines CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $4.26 on January 1st, 2026. Since then, CTMX shares have decreased by 45.1% and is now trading at $2.34. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company had revenue of $1.42 million for the quarter, compared to analysts' expectations of $12.39 million. CytomX Therapeutics had a negative net margin of 435.21% and a negative trailing twelve-month return on equity of 38.46%. Read the conference call transcript. When did CytomX Therapeutics IPO? CytomX Therapeutics (CTMX) raised $100 million in an IPO on Thursday, October 8th 2015. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.54%), Peak Financial Advisors LLC (0.21%), Robertson Stephens Wealth Management LLC (0.10%) and Profund Advisors LLC (0.04%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Christopher Ogden, Yu-Waye Chu, Lloyd A Rowland and Jeffrey B Landau. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), SoundHound AI (SOUN), Advanced Micro Devices (AMD), Palantir Technologies (PLTR) and Tesla (TSLA). Company Calendar Last Earnings8/06/2026Today10/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, CTMX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CTMX CIK1501989 Webwww.cytomx.com Phone(650) 515-3185Fax650-351-0353Employees69Year Founded2008Price Target and Rating Average Price Target for CytomX Therapeutics$11.90 High Price Target$16.00 Low Price Target$6.00 Potential Upside/Downside+408.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.37 million Net Margins-435.21% Pretax Margin-433.95% Return on Equity-38.46% Return on Assets-30.33% Debt Debt-to-Equity RatioN/A Current Ratio9.36 Quick Ratio9.36 Sales & Book Value Annual Sales$76.20 million Price / Sales6.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book4.03Miscellaneous Outstanding Shares217,900,000Free Float209,619,000Market Cap$509.89 million OptionableOptionable Beta2.21 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CTMX) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
